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Figure legends 
Figure 1.  Illustration of the TEAMS CDSS tool used by nurse for data entry and guideline based 
assessments during telemedicine visits (left), including built-in patient educational modules from 
the Let's Talk About Asthma series for smartphone (right)  
 
Online supplemental materials legend 
Figure E2.   Sample progress note auto-generated by the TEAMS CDSS tool 
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Abstract 
Background: Technology-based interventions that can function within real-world practice and 
improve outcomes without increasing provider burden are needed, yet few successfully cross the 
research-to-practice divide. This paper describes the process of developing a clinically-integrated 
smartphone-telemedicine program for adults with asthma and results from proof-of-concept 
testing.    
Methods:  To ensure integration with practice, we used a contextually-grounded intervention 
development approach and May's implementation theory to design the intervention, with 
emphasis on systems capabilities and stakeholder needs.  The intervention incorporated symptom 
monitoring by smart phone, smartphone telemedicine visits and self-management training with a 
nurse, and clinical decision support software, which provided automated calculations of asthma 
severity, control, and step-wise therapy.  Seven adults (aged 18-40) engaged in a 3-month beta-
test.  Asthma outcomes (control, quality of life, FEV1) and healthcare utilization patterns were 
measured at baseline and end-of-study.   
Results: Each participant received an average of 4 telemedicine visits with 94% patient 
satisfaction.  All participants had uncontrolled asthma at baseline; by end-of-study 5/7 classified 
as well controlled. Mean asthma control improved 1.55 points (CI=0.59-2.51); quality of life 
improved 1.91 points CI=0.50-3.31), and FEV1 percent predicted increased 14.86% (CI=-3.09-
32.80) with effect sizes of d=1.16, 1.09, and 0.96, respectively. Preventive healthcare utilization 
increased significantly (1.86 visits/year vs. 0.28/year prior, CI 0.67-2.47) as did prescriptions for 
controller medications (9.29 refills/year vs. 1.57 refills/year, CI 4.85-10.58).   
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Conclusion:  Smartphone telemedicine may be an effective means to improve outcomes and 
deliver asthma care remotely. However, careful attention to systems capabilities and stakeholder 
acceptability is needed to ensure successful integration with practice. 
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Introduction 
Asthma remains one of the most common chronic health conditions, affecting 8.2% of 
adults, of which approximately 63% have persistent symptoms.1, 2 Typically, correct use of 
controller medication and effective self-management can alleviate symptoms, prevent 
exacerbations, and reduce risk of long-term lung damage.3 Yet while morbidity and mortality 
due to asthma are preventable, nearly 62% of adults with asthma remain uncontrolled, and 
implementation of potentially effective new interventions within real-world contexts has been 
limited.4 
There is no doubt that careful assessment, close follow-up, medication reminders, and 
self-management training all improve adherence and outcomes.4  However, these approaches 
require personnel and time resources that may not exist within over-burdened healthcare 
systems.  With the growing shortage of primary care providers (PCP) and the increasing 
complexity of clinical care, it is unlikely that PCPs can carve out additional time to focus on 
asthma management.5  For this reason, interventions that can function effectively within existing 
systems’ constraints and improve patient outcomes without increasing provider burden are 
urgently needed. 
There is growing evidence that use of e-health technology (e.g. smartphones, electronic 
medical record, and computer decision-support software "CDSS") can address common asthma 
management issues.6, 7   However, most technology-based interventions do not integrate with the 
electronic medical record (EMR), and are thus not currently clinically sustainable.  While 
researchers may be optimistic about the ability to integrate ex post facto, few tech-based 
interventions cross the research to practice divide, typically due to unforeseen systems 
implementation issues or incompatibility with existing clinical workflow. 
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Thus, in designing a new technology-based intervention for asthma management, we 
adopted a contextually grounded intervention development approach that allowed for 
consideration of implementation issues during the development process 8.   Specifically, we 
sought to develop a smartphone-based telemedicine program that could address common asthma 
management problems (e.g. patient non-adherence,9-11 inaccurate symptom reporting,12, 13  poor 
self-management,14, 15 access to care,16-18 and provider nonadherence to asthma guidelines19-21) 
and integrate with the EMR and existing clinical practice.  The goal in developing the 
intervention was to increase the accuracy, effectiveness, and convenience of care for patients, 
while avoiding increased clinician burden and promoting adherence to guidelines.22-26  In this 
manuscript, we describe the process of contextually grounded intervention development, the 
resulting technology, and proof of concept testing in a small, real-world sample of adult patients 
in a large urban medical center.  We hypothesized that the intervention would show preliminary 
evidence of feasibility and acceptability and potential to improve asthma outcomes in younger 
adults with asthma.    
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Methods 
Intervention Development  
As shown in Table 1, we navigated an extensive two-year planning and development 
process aligning with May's implementation theory,27 including identifying problems and 
solutions, target environments, system capabilities, key stakeholders, practice policies, and 
credentialing processes.  Development required establishing key relationships; assembling a 
representative team, creating and testing the technology, obtaining approval to launch, and proof-
of-concept testing with patients in the clinical setting. 
Technology Enabled Asthma Management System (TEAMS) is a fully integrated EMR-
based intervention designed for use in primary care.  Based on the process described above, three 
technological components were selected to augment routine asthma care: (a) remote smartphone 
symptom monitoring, (b) synchronous smartphone telemedicine follow-up and self-management 
training with a nurse, and (c) computer-guided EMR assessments using built-in clinical decision-
support software (CDSS).  Patients recorded home-entered symptoms using their smartphones 
and a patient portal app (Mychart; Epic Systems Corporation, Wisconsin USA), which uploaded 
symptom data directly to the Epic EMR. One nurse (JRM) conducted telemedicine visits using 
Zoom's HIPAA-compliant secure video-conferencing platform (Zoom Inc. California USA).  
The nurse reviewed home-entered symptoms and entered a detailed asthma assessment into the 
TEAMS CDSS flowsheet (see Figure 1), which is a complex clinical documentation and 
decision-making tool embedded in the EMR.  Guideline-based algorithms in the CDSS tool 
instantaneously calculated asthma severity, control, and provided a comparison of recommended 
versus prescribed step-wise therapy. The CDSS tool was designed to improve assessment 
accuracy, guide step-wise medication management,4 inform providers, and help patients achieve 
TECHNOLOGY ENABLED ASTHMA MANAGEMENT SYSTEM (TEAMS) 
better asthma control. Results of the analyses were shared with the participant and evidence-
based self-management training was provided using the free online resource Let's Talk About 
Asthma! e-series for smartphone developed in our prior work.28, 29 A detailed progress note 
autogenerated by the CDSS tool (see Figure E1, online supplement) was filed in the EMR for 
each telemedicine visit. Per protocol, an EMR InBasket message with a visit summary was sent 
to the PCP team if the patient had uncontrolled asthma and needed medication adjustments or 
office follow-up, with a back-up phone call for urgent issues.  To ensure safety and monitor for 
correct functioning of EMR algorithms, all telemedicine visits in this phase were conducted by 
an advanced practice nurse with IT training (JRM), and each calculated output was verified for 
accuracy.   
CDSS calculations used National Asthma Education Prevention Program guidelines4 but 
are adaptable to other guidelines. Program components are likely compatible with other EMRs. 
Approach (Proof-of-concept testing) 
This study was approved by the University of Rochester Internal Review Board 
(RSRB67900). A mixed methods approach was used.  The quantitative portion consisted of a 
single-arm pilot study with pre-post and longitudinal collection of outcomes over 3 months 
(asthma control, quality-of-life, Forced Expiratory Volume (FEV1), ED visits, hospitalizations, 
feasibility/acceptability surveys). The qualitative portion used descriptive methodology and 
open-ended interviews to capture patients’ experiences and perceptions of TEAMS, to explore 
acceptability and perceived impact. Staggered enrollment was used to account for seasonal 
variation in symptoms. 
Setting and sample  
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Participants were randomly selected from clinic rosters in an urban safety-net resident-
run primary care clinic in Western NY.  Eligibility criteria were: ages 18-40, with any diagnosis 
of current asthma, English speaking, and having a smartphone.  Age range was restricted to 
younger adults (18-40 years) on the basis of smartphone prevalence and technology uptake. 
Patients with confounding comorbidities (e.g. heart failure COPD, Cystic fibrosis) and pregnant 
patients were excluded. Patients with psychiatric diagnoses were not excluded. Ten patients, 
randomly selected from clinic rosters, were screened; all had smartphones.  One was ineligible 
on the basis of heart failure and two who were eligible could not be re-contacted after screening.  
The remaining seven consented and completed the beta-test (3-month duration). 
Intervention delivery 
Written informed consent and all study procedures were performed by a trained non-
medical research assistant in patients’ homes due to high office-visit no-show rates. Technology 
set up and training occurred at the baseline visit.  Participants were asked to record symptoms, 
medication use, and Peak Expiratory Flow (PEF) using a Microlife30 digital peak flow meter 
(Microlife, USA) via smartphone, daily, for 3 months.  A nurse (JRM) initiated follow up 
smartphone telemedicine visits with patients every 2-weeks until asthma control was achieved, 
as calculated by the TEAMS CDSS tool. All visits were scheduled by text messaging and text 
message reminders were sent the day prior to or the day of appointment.  Following each visit, if 
the CDSS tool indicated that the patient's asthma was uncontrolled, a brief synopsis was sent to 
PCP via EMR InBasket messaging with urgent messages also conveyed via phone call.   The 
PCP then initiated medication adjustments via e-prescribing, if warranted, and determined 
medically appropriate follow-up.  The TEAMS nurse then helped to coordinate care and ensure 
follow up.  Once the patient achieved good asthma control, follow up frequency decreased to 
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once a month. There was no minimum requirement for participation in self-monitoring or 
telemedicine visits and patients participated in each activity as often as they were motivated to.  
Intervention dose for each participant was tracked and correlated with outcomes.  
Outcome Measures 
Feasibility was measured by: (a) frequency of participation in symptom monitoring, (b) 
number of visits needed to achieve/maintain asthma control, (c) duration of visits, and (d) no 
show and reschedule rates.  Similar to clinical practice, length of visit was driven by the time it 
took to complete the asthma assessment, teach participants specific self-management skills, and 
relay follow up documentation to PCP/clinic.  Thresholds for minimum or maximum 
intervention dose were not predefined, as the goal was not to deliver a standard intervention 
dose, but to assess dose needed to achieve good control or dose tolerated (e.g. frequency of 
voluntary participation), and relationship between intervention dose, asthma control, and quality 
of life.   
Efficacy. Primary outcomes (asthma control, quality of life, and FEV1 percent predicted) 
were collected at baseline and end of study. Asthma control and quality of life were measured 
using the Asthma Control Questionnaire (ACQ)31 and Asthma Quality of Life Questionnaire 
(AQLQ), respectively.32   
ACQ. The ACQ is a well-established 7-item questionnaire with a score range of 0-6 
(lower scores represent better control).  A score of  ≦0.75 has a positive predictive value of 0.85 
for controlled asthma, and a score of ≧ 1.5 has a positive predictive value of 0.88 for 
uncontrolled asthma.31 Minimum important difference is a change score of 0.5.33  
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AQLQ.  The AQLQ measures physical and emotional impact of disease with high test-
retest reliability (>0.90).32 Averaged total scale and subscale scores range from 1-7, with higher 
scores representing better quality of life.  Minimum important difference is 0.5 per domain and 
overall quality of life.34 
FEV1 was measured using Microlife digital PFMs.30  FEV1 percent predicted was 
calculated using NHANES III criteria.35, 36 Number of prescriptions written by providers for 
asthma medications were obtained through EMR review for the year pre and post intervention.  
Actual refills by patients could not be accurately determined due to external pharmacies data 
storage procedures. 
Acceptability was assessed at the end of the study through 1:1 interview and the Usability 
Satisfaction and Ease of Use Questionnaire (USE-Q). The USE-Q37 is a validated 21-item 
instrument with a 7-point Likert scale format (1=strongly disagree to 7=strongly agree). Higher 
scores represent more positive perceptions, with 7 being the most positive possible score and 1 
representing the most negative possible score. Minimum acceptability thresholds were a score 
≥5=somewhat agree on at least 70% of USE-Q items.  Exit interviews were conducted to 
qualitatively explore acceptability. 
Demographics were collected via survey and the EMR. 
Data analysis 
 Descriptive statistics were computed for demographics, feasibility, and USE-Q data.  
Paired t-tests were used to compare baseline and end of study scores for ACQ, AQLQ, and FEV1 
percent predicted, and effect sizes (Cohen's d) were calculated. Unadjusted bivariate correlation 
was used to explore associations between asthma control and quality of life (ACQ, AQLQ) and 
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intervention dose (frequency of self-monitoring and telemedicine visits).  Audio-recorded 
interviews were transcribed and qualitative content analysis techniques38 were used to explore 
participants’ perceptions of the program. 
Results 
Baseline asthma and demographic data are presented in Table 2. 
Feasibility. Of 42 scheduled telemedicine visits, 7 were no-shows (16%; involving 4/7 
patients), 7 rescheduled (16%; involving 4/7 patients), and 28 were conducted as expected 
(68%).  Participants averaged 4 telemedicine visits (range 3-5), for a grand mean of 114 minutes 
spent with the asthma telemedicine nurse (range 88-160 minutes; SD 25.07; average 61 minutes 
self-management training and 53 minutes nursing-assessment per participant).  Participants 
logged symptoms remotely an average of 32 days over 3 months (range 15 to 64; SD 15.56). 
Participants were asked to set a daily reminder on their smartphone; no external reminders were 
provided for self-monitoring.  Average telemedicine visit duration was 29 minutes (range 20-45 
minutes), and the majority of visits (17/28; 61%) were delivered after 5pm or on weekends to 
accommodate participants’ work schedules.     
Efficacy. At baseline, all participants had uncontrolled asthma. At 3-months, 6/7 
participants had marked reduction in symptoms with 5/7 classifying as well-controlled 39.  Effect 
sizes were large for improvements in control, quality of life, and FEV1 percent predicted (d=0.96 
to 1.16). Table 3 shows pre-post scores for asthma outcomes with effect sizes and confidence 
intervals.   On average, asthma control improved 1.55 points—more than 3 times the clinical 
MID.  Significant improvements were seen in morning symptoms, night time wakening, activity 
limitations and shortness of breath, with greatest effects on reductions in wheezing (d=1.48). 
Quality of life improved an average of 1.91 points, nearly 4 times the minimum important 
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difference (MID).  Improvements were evenly distributed across all domains (symptoms, activity 
limitations, emotional functioning, and environmental stimuli.  There was also an average 
increase of approximately 15% in FEV1 percent predicted. 
Table 4 shows individual peak flow graphs (extracted from the EMR) with a noticeable 
upward trend in PEF for most participants.  Graphs for the first two participants showed 
downward or neutral trends.  Association between number of days participants performed home 
self-monitoring, length of visit, and improvement in asthma control was moderate (r= 0.67 and 
p=0.10). 
An average of 2 (range 1-4; SD 1.29) InBasket messages per participant were sent by the 
TEAMS nurse to the participants' PCP (n=4) over 3 months, to coordinate follow-up care and 
medication adjustments, with 100% PCP response. As seen in Table 3, there were significant 
and clinically meaningful increases in use of preventive health services and written prescriptions 
for controller medications, and a corresponding decrease in prescriptions for oral corticosteroids 
in the year following intervention. 
Acceptability.  As shown in Table 5, acceptability and satisfaction was high (93.9%).  At 
exit interviews, six of seven participants reported that the intervention “changed my life” and 
enabled them to take control of their asthma for the first time.  Qualitative data on the perceived 
impact of the intervention are presented in Table 4.
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Discussion 
Data from this proof-of-concept study suggest that use of an integrated smartphone and 
EMR/practice-based intervention might be an effective means to supplement primary asthma 
care and improve outcomes.  The underlying importance of this approach lies in the ability to 
reduce barriers to accessing primary care.18  Telemedicine is inherently more flexible than office 
care, and does not require that patients travel to a given location.  Extending telemedicine into 
patients' homes via ubiquitously available smartphones could make communities the front-line 
for primary care.  Because of ability to supersede geographic boundaries, smartphone technology 
could increase clinical reach, and may thus be the key to delivering care to underserved 
populations locally and globally.  
Prior studies have demonstrated that use of remote monitoring, self-management training, 
telemedicine, smartphones, and CDSS tools, individually, can improve outcomes.40-42  To our 
knowledge, however, this is the first intervention to combine these components into a single 
technological package that effectively integrates with real-world medical practice and the live 
EMR.   
In contrast to studies that have sought to isolate and quantify the impact of individual 
factors,43, 44 this study adopted a broad-spectrum approach with simultaneous intervention across 
multiple patient, provider and systems levels, as we theorized that the impact of a multifaceted 
program would likely be different from the impact of individual components in isolation 45, 46.  
The marked improvement in outcomes, as evidenced by large effect sizes on key outcomes 
(d=0.96 to 2.62), supports this holistic approach.  On average, participants achieved a 15% 
increase in FEV1, crossing the critical clinical threshold of >80%.39  Additionally, improvements 
in asthma control and quality of life that were 3-4 times the minimum important difference.31, 34  
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Patients’ perceptions of acceptability and feasibility were high, and while participants only 
recorded symptoms only 33% of the time on average, greater engagement was associated with 
improved asthma control.  Lastly, the significant increase in written prescriptions for controller 
medications and in-office PCP follow up suggest that the intervention can promote provider 
adherence to guideline-based care, in addition to improving patient specific outcomes.20, 47   
From a systems standpoint, clinical feasibility and affordability has yet to be determined.  
In this small sample, no-show and reschedule rates for telemedicine visits was only slightly 
better than office visit attendance rates (66%), with 68% of telemedicine visits conducted as 
expected 48.  Further research is needed to determine cost-effectiveness and institutional 
capability to run a program that operates heavily during evening and weekend hours.  
Furthermore, given that participants required an average of 114 minutes of individualized asthma 
education with a nurse to achieve and maintain control, the TEAMS approach is likely to require 
greater upfront investment by insurers and the medical community to achieve long-term societal 
gain.  Yet, it is abundantly clear that current approaches to "feasible and affordable care" are not 
effective, as the majority of patients with asthma remain chronically uncontrolled.   Thus, it may 
be necessary to stretch healthcare boundaries and explore ways to make effective care affordable, 
rather than perpetuating systems that are affordable but largely ineffective. In short, moving 
towards an aggressively proactive rather than reactive approaches to asthma management is 
essential to changing long-term health trajectories.46 
Limitations. This proof-of-concept study used a small sample. Patients were 
predominantly younger, minority, lower SES, lower health-literacy, with moderate/severe 
uncontrolled asthma, and the intervention was delivered by a single nurse.  Further research in a 
larger and more representative population, with diverse interventionists is needed to replicate 
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findings, evaluate who the intervention is most effective for, and determine if all intervention 
components are necessary to achieve similar outcomes.   
Despite limitations, we believe these data are compelling, and the processes delineated 
herein will be useful to those seeking to develop and implement technology-based clinical 
interventions. Several important lessons were learned:  First, the technology took nearly two 
years to conceptualize, build, and integrate into practice, which was longer than anticipated.  The 
majority of this time was spent navigating systems level barriers, gaining access to EMR 
build/programming environments, and getting healthcare provider buy-in.  It is well-known that 
many potentially effective interventions are never integrated into clinical practice or the EMR.  
Our experience suggests that this may be partly due to failure to account for powerful real-world 
constraints.  As seen throughout the development process (Table 1), we found that wherever the 
intervention disrupted existing practice (even by small amounts), it was met with resistance.  
Conversely, by avoiding workflow changes and carefully incorporating stakeholder feedback, we 
were able to minimize resistance and increase support for the intervention.  It is also worth 
noting that even with using a contextually-grounded intervention development approach, where 
the intervention was crafted to the clinical context, there was still need for additional on-the-
ground customization to account for unanticipated barriers (e.g. trouble engaging patients in 
office settings; preference of clinic providers to delegate use of the CDSS tool to nursing care).  
Thus, the final intervention that was implemented was noticeably different than originally 
conceptualized.  Use of focus groups, interviews, community engagement studios, and close 
collaboration with key stakeholders are important precursors to developing a clinically 
sustainable intervention.27  Additionally, careful negotiation of institutional practices for new 
EMR build and IT and administrative support will be essential, as there are substantial barriers to 
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new technology within the EMR due to potential for far-reaching negative systems impact.  
Based on these experiences, we conclude that use of advanced EMR, CDSS, and smartphone 
technology has strong potential to improve asthma care, but premature intervention development 
without sufficient groundwork could be detrimental to long-term success. 
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TABLE 1.   Process of contextually grounded intervention development 
 





• Identify target population and specific problems 
• Assess population capabilities, barriers, facilitators 
• Define approaches that might work for problem and 
population using prior evidence and theory 
Population: Adults at risk for uncontrolled asthma (urban, minority, 
underserved, low SES, low health literacy) 
Problems: Poor access to care; No show and transportation issues, 
Nonadherence; Poor follow-up; Poor self-management. 
Opportunity: 85% adults < 40 years use smartphones regularly 
Target 
environment 
• Identify environments with access to target population 
• Assess clinical capability, preparedness, and willingness 
to adopt a new intervention  
• Identify current clinical structure (physical resources, 
ways of operating, workflow and scheduling patterns) 
• Develop awareness of general and specific barriers 
(staff, provider, or clinic resource limitations) 
• Determine approaches that might work for clinical 
context, patient population, and identified problems 
Environment:  Urban primary care “safety-net” practice 
• Practice willing to support a tech-based asthma intervention if no negative 
impact on workflow 
• EMR/smartphone intervention run by nurses would be acceptable and 
integrate with practice 
• Modification to work flow/documentation patterns would not be supported 
by providers due to increased work burden 
• Limited availability of clinic appointments = delayed follow up. 
• Hours of operation: Weekdays until 4:30pm, conflicts with patient needs for 
afterhours and weekend care 
System 
capabilities 
• Identify system capabilities (technological, 
programmatic, IT resources, supports/barriers) 
• Identify implementation barriers (e.g. moratorium on new 
EMR build, anticipated build time and available build 
resources (personnel and systems access issues), 
willingness to support novel research-based build) 
Capabilities: Symptoms can be monitored remotely with smartphones via 
patient portal to EMR interface 
• Guideline-based algorithms and decision support tools in EMR can 
minimize inaccuracies in clinical care 
• Home-based telemedicine can improve access to care  
Barriers:  institutional cap on EMR build > 10 hours - requires formal review 
for priority and funding; research considered lower priority than clinical 
applications; limited funding available; initial plan to have clinic nurses do 
telemedicine visit was found to be non-viable due to patient need for evening 
and weekend visits, resulting in use of dedicated nurse interventionist  
Key 
stakeholders 
• Define potential impact of intervention (development and 
implementation) on patient, staff, and systems revenue 
or resources to identify stakeholders 
• Recognize and respect needs and perspectives of 
stakeholders who may impact intervention uptake (e.g. 
patient, community, support staff, nursing, provider, 
administrative, IT and data security, research, reporting, 
insurers) 
Interviews and community engagement studios to engage: 
• Admin: (support for hybrid clinical/research program) 
• Medical faculty (support for program w/ Resident participation) 
• Residents: (support shared patient management; in-basket notification of 
nursing assessments; not supportive of any workflow change/disruption; 
low interest in using CDSS) 
• Nursing: (gatekeeper for clinical communication pathways; open to 
workflow changes if practicable, interested in maximizing scope of 
practice, including use of CDSS and telemedicine follow up) 
• IT department (gatekeepers for new build; review/approve build) 
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• Research community (requires rigorous science/data) 
• Patient and community (feedback on design, problems) 
Practice 
policies 
• Identify practice policies and incorporate into design  • Factor for established communication pathways, scheduling procedures, 
usual follow up protocols 
• Identify internal "champions" who can facilitate implementation 
Credentialing 
and approval 
• Determine what certifications may be necessary to 
obtain approval or facilitate development of the 
intervention (e.g. specific build or reporting certifications) 
• Identify needed permissions (e.g. IRB, clinical 
administration, provider/staff approvals or “buy-in”)  
• (Urgent) Epic builder certification of researcher needed due to limited build 
resources; EMR build had to be performed by researcher, and 
administrative approval was needed at multiple levels to support this 




• Identify immediate funding sources and potential for 
long-term sustainable funding 
• Immediate: departmental and research funding 
• Eventual: foundation funding → insurer reimbursement  
• Current insurer policy does not reimburse for site to home telemedicine by 
nursing for asthma care; however demonstration of long-term cost savings 





the team  
• Representative of key internal stakeholders 
• Relationships: Faculty/staff, patient and community, administrative, clinical, 
research, and information technology  




technology –  
a systems 
approach 
• Translate guidelines to algorithms conceptually 
• Draft (code), revise and test technology 
• Build for compatibility with existing workflow 
• Minimize disturbances to current clinical patterns 
• Seek additional feedback from key stakeholders  
• Modify algorithms and output based on feedback 
• Determine quantity, granularity, and specificity of data capture (categorical, 
interval, or narrative) 
• Determine approach to data entry (e.g. smartform, flowsheet)  
• Assess if data capture approach is well situated for reporting and statistical 
analyses and impact on workflow of data entry method 
• Identify evidence-based guidelines and write code for CDSS 
• Obtain expert review of CDSS (clinician, pharmacist, nursing) 
• Test program comprehensively for analytic functioning—200 unique 
clinical scenarios evaluated across multiple iterations 
• Design + test CDSS auto-generated progress note, obtain clinician review 





• Review of the final product by stakeholders • Clinic permission to launch 
• IRB approvals 
• Beta testing with patient feedback and revision as indicated 
Notes:  CDSS=Clinical decision support software; EMR=Electronic medical record; IT=Information technology; SES=Socioeconomic status 
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TABLE 2. Sample Baseline Characteristics (n=7) 
Variable N (%) 
Single (% Yes) 6 (86) 
Low incomea (% Yes) 5 (71) 
Employed full time (% Yes) 5 (71) 
Public insurance (% Yes) 4 (57) 
High School Graduate (% Yes) 5 (71) 
Sex (% Female) 6 (86) 
Comorbid mental illness (% Yes)b 5 (71) 









Any Controller Medication Use Past Month (% Yes) 3 (43) 
















 Mean (SD) 
Age 29.5 (5.22) 
Years diagnosed with asthma 16.57 (8.33) 
a Low income:  < 200% US Federal poverty level ($12,140 individual; 
$25,100 for a family of four)49 
bMental illness: bipolar, PTSD, panic disorder, anxiety/depression 
cSubstance use disorders: marijuana, tobacco, alcohol 
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1.16 0.007 0.59-2.51 






1.09 0.045 0.075-1.93 






1.28 0.038 0.052-3.66 






0.66 0.017 0.40-2.75 













1.48 0.011 0.61-3.10 






0.46 0.20 -0.60-2.31 






1.09 0.016 0.50-3.31 






1.17 0.009 0.79-3.61 






0.82 0.037 0.12-2.79 






1.27 0.032 0.28-4.29 













0.96 0.089 -3.09-32.80 















0.52 0.356 -0.41-0.98 






2.62 0.005 0.67-2.47 








2.47 0.001 4.85-10.58 






1.14 0.044 0.22-12.34 






0.47 0.457 -0.59-1.17 
Abbreviations. ACQ=Asthma Control Questionnaire; AQLQ=Asthma Quality of Life Questionnaire;  OCS=oral 
corticosteroid; SABA=short acting beta agonist 
aMinimum important difference = 0.5 per domain and total score; Large effect size (d) is considered >0.80;  
TECHNOLOGY ENABLED ASTHMA MANAGEMENT SYSTEM (TEAMS) 





Graph of daily PEF 
(extracted from EMR)  
Baseline → End 
Measure Pre Post 







ACQ 4 4 [Before] I didn’t realize my asthma wasn’t controlled, I was 
wheezing but I just thought I had a cold all the time.… I 
thought I was doing pretty good even though I be out of 
breath.  But when I started using [the peak flow] I saw the 
numbers and realized I couldn’t breathe, and that made me 
want to get my lungs healthy … I’ll be honest, I didn’t used to 
take my pump, but now I use it every day.  
AQLQ 2.43 1.19 
FEV1%pred 67 68 
# Televisits  3 






ACQ 2.14 1.29 The program helped me recognize the symptoms of my 
asthma…I learned if you don’t take your control medicine you 
can scar your lungs—that got me to pay attention! Now that 
I’m daily taking my medicine—it’s given me a whole ‘nother 
breath…I thought I didn’t need it, ‘til I found out how to use it 
and what it does for your body.  I’m recommending this to my 
family and friends—I’m spreading the word! 
AQLQ 3.97 5.84 
FEV1%pred 85 84 
# Televisits  4 






ACQ 5 1.71 I realized I have the right to control my asthma. First time we 
met I was crying cause all I wanted to do is breathe, but I felt 
powerless. This changed my life—I’m like 100% better. 
[Before] I didn’t use my inhalers cause of how I was raised. 
Now I take my [control inhaler] every day. … I had a 
medication that could’ve been helping me the whole time, but I 
didn’t know what it was for, so I’m not gonna take it! 
AQLQ 1.88 4.59 
FEV1%pred 46 100 
# Televisits  5 





ACQ 2.29 0.43 I used to have symptoms for hours every day, and now I 
almost never do. I take my control inhaler every day and I 
work out—and I couldn’t do that before. And before, if I had an 
asthma attack, I wouldn’t take my inhaler, I would’ve just 
called the ambulance and gone to the hospital. But [now] I 
take it and it works! I have the knowledge and confidence that 
I can take care of myself—This changed my life!    
AQLQ 4.41 6.94 
FEV1%pred 102 103 
# Televisits  4 






ACQ 2.43 0.43 I’m not really having symptoms anymore, maybe once a week.  
Before I was wheezing all the time, and I didn’t have any 
medication, and I didn’t know what was causing it. I was 
suffering. Now, I take my control medication every day. It 
takes a load off a person when you get the education and you 
can monitor it and control it…it changed my life dramatically. I 
can breathe, and I can control it. I feel like a regular person. 
It’s amazing. I recommend anyone do this.  
AQLQ 3.28 6.88 
FEV1%pred 85 95 
# Televisits  3 






ACQ 1.57 0.29 I’m more aware and more educated about my symptoms now, 
and I take my control meds every day. I used to wait out my 
symptoms, thinking “it’ll go away, it’s OK.” I’m less accepting 
of symptoms now because I know I’m doing damage—I was 
never taught that. It’s kind of embarrassing …I’m a nurse and I 
should’ve known these things.  Now I can better educate my 
patients and even my doctors.   
AQLQ 5.50 6.81 
FEV1%pred 80 103 
# Televisits  5 






ACQ 1.71 0.29 (Crying) Six months ago I was scared. I was out of work for a 
month because of asthma. Now I’m not scared and I know 
what to do to prevent something small from getting big. 
Before, I never paid for my control inhaler because it was 
expensive and I didn’t know why I should get it when I could 
use the cheap one. I don’t freak out now if I leave home 
without my rescue inhaler because I almost never need it.   
AQLQ 4.47 6.94 
FEV1%pred 68 84 
# Televisits  4 
# Entries  36 
Notes.  aEntries = home entered symptoms.  AA=African American; ACQ=Asthma Control Questionnaire (Range 0-6; Lower scores represent better 
asthma control; < 1.5 is predictive of controlled asthma); AQLQ=Asthma Quality of Life Questionnaire (Range 1-7; Higher scores represent better 
quality of life); C=Caucasian; HL= Hispanic/Latino; F=Female; M=Male; P#=Participant(#); Visits=Telemedicine visits with a Nurse; Recordings=daily 
home symptom and peak flow recordings via smartphone patient portal.  (PEF graph images extracted from the EMR show peak flow over time and 
have been flipped to display data in left to right chronological order. PEF images © 2019 Epic Systems Corporation. Used with permission. 






TABLE 5.  Item scores for the Usability, Satisfaction and Ease of Use Questionnaire 
 Mean  
Range 
(1-7) SD  
It helps me be more effective. 7 7 0 
It helps me be more productive. 6.86 6-7 0.378 
It is useful. 6.71 6-7 0.488 
It gives me more control over the activities in my life. 6.71 6-7 0.488 
It makes the things I want to accomplish easier to get done. 6.43 4-7 1.134 
It saves me time when I use it. 6.14 4-7 1.215 
It does everything I would expect it to do. 6.43 4-7 1.134 
It is easy to use. 6.29 5-7 0.951 
It is easy to use. It is simple to use. 6.86 6-7 0.378 
It is user friendly. 6.86 6-7 0.378 
It requires the fewest steps possible to accomplish what I want 
to do with it. 6.57 5-7 0.787 
I learned to use it quickly. 6.57 5-7 0.787 
I easily remember how to use it. 6.57 6-7 0.535 
It is easy to learn to use it. 6.71 6-7 0.488 
I am satisfied with it. 6.86 6-7 0.378 
I would recommend it to a friend. 6.57 5-7 0.787 
It is fun to use. 6.43 4-7 1.134 
It works the way I want it to work. 6.43 4-7 1.134 
It is wonderful. 6.43 5-7 0.976 
I feel I need to have it. 6.14 3-7 1.574 
It is pleasant to use. 6.43 4-7 1.134 
Average score for survey 6.57 5.6-7 0.654 
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Figure 1.  Illustration of the TEAMS CDSS tool used by nurse for data entry and guideline based assessments during 
telemedicine visits (left), including built-in patient educational modules from the Let's Talk About Asthma series for 
smartphone (right) Copy right J Mammen, used with permission
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Figure E1.   Sample progress note auto-generated by the TEAMS CDSS tool 
Progress note 
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Asthma telemedicine visit summary xx/xx/xxxx: 
• Assessment: Very Poorly Controlled, likely Severe persistent asthma based on prescribed medications and 
symptom pattern. 
• Prescribed: SYMBICORT 160-4.5 mcg ( Budesonide-Formoterol MDI ) at a MEDIUM dose (640 mcg daily) 
and is currently taking 2 puffs in the morning and 2  puffs at night (640 mcg daily - MEDIUM dose) 
• Other asthma control medications: NONE (taking cetirizine for allergy) 
• Recommended stepwise therapy is Step 5.   
• The patient is currently taking Step 4 - Insufficient control medication 
• Plan: Schedule office visit with PCP, Follow up virtual visit in 2 weeks 
  




XXX was seen via Zoom (telemedicine) for nursing follow up of Asthma.   
The patient reports the following: 
 Daytime symptoms 
          Well controlled <= 2 x week 
  Every day, throughout the day (maybe 2-3x day, 
mostly morning or evening).  Notes recurrent chest 
discomfort which resolves with albuterol 
 Night time wake up from asthma 
       Well controlled <= 2 x month 
  Wakes three nights a week 
 Use of rescue inhaler for symptoms 
       Well controlled <= 2 x week 
  Using inhaler many times a day 
 Activity limitations 
         Well controlled = none 
  Some limitation 
  
Patient perceived asthma control: Very poorly controlled 
Current respiratory illness: Feels fine 
Any smoking in the past 6 months: Yes 
Any symptoms of life-threatening asthma: No 
  
NOTES: noticing chest discomfort all day, a pain with deep breathing, pain resolved with taking albuterol and 
stays away for 3 to 4 hours then returns. 
  
MEDICATION USE: 
Prescribed:  SYMBICORT 160-4.5 mcg ( Budesonide-Formoterol MDI ) and is currently taking 2 puffs in the 
morning and 2  puffs at night (MEDIUM dose)—fully adherent. 
Low dose is equal or less than 540mcg; High dose is greater than 1080mcg 
  
Taking any additional long acting beta agonist or leukotriene inhibitor: NONE (taking cetirizine for allergy) 
Rescue medication: Albuterol inhaler - used about 4-5 times a day - takes prior to AM/PM Symbicort as 
recommended, and then a couple of times during the day 
Most recent patient self-reported data (MyChart smartphone monitoring) shows: 
 
  4/16/2019 4/15/2019 4/14/2019 4/5/2019 4/3/2019 4/1/2019 
Time  6:00 AM  7:01 AM  9:22 AM  7:52 AM  5:44 AM  2:23 PM 
Did you have ANY 
SYMPTOMS of 
asthma in the 
past 24 hours? 
I had SOME 
asthma 
symptoms 
I had SOME 
asthma 
symptoms 
I had SOME 
asthma 
symptoms 
I had SOME 
asthma 
symptoms 
I had SOME 
asthma 
symptoms 
I had SOME 
asthma 
symptoms 
What was your 358 357 352 401 318 533 
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PEAK FLOW 
today?  
   
OBJECTIVE 
  
Appears well - Normal effort with respiration 
Peak flow today via digital PEF meter is 481 L/min, which is 100% of personal best (481)       
FEV1 (today): 3.35    FEV1 Predicted: 4.15        • FEV1 % of predicted: 81 
     • FEV1 or PFM Zone: Green 
 ASSESSMENT  
  
No current safety concerns: Symptoms have decreased over all, but noticing regular chest discomfort -  needs to 
follow up in office ASAP and may need stepwise increase to bring symptoms under control faster.  Should follow 
up ASAP for chest pain. 
  
EPR-3 calculated asthma assessment: 
Asthma control: Very poorly controlled 
Asthma severity (EPR3): Severe persistent asthma 
Guideline based assessment of controller therapy: Insufficient control medication 
     • Guideline recommended stepwise therapy: Step 5 
     • Provider prescribed stepwise therapy level: 4 
     • Patient using stepwise therapy level: 4 
     • Recommended ICS adjustments: Taking maximum dose prescribed by provider 
     • Recommended follow up: Follow up with PCP ASAP 
  





Asthma Education covered this visit:   
 What is asthma + what causes symptoms    
 What happens when asthma is uncontrolled  Demonstrates understanding 
 How do you know if your asthma is controlled?  Demonstrates understanding 
 Control vs. rescue medications  Demonstrates understanding 
 Recognizing symptoms of asthma  Demonstrates understanding 
 What to do during an asthma attack  Demonstrates understanding 
 Life threatening asthma symptoms  Demonstrates understanding 
 How to take inhalers correctly  Demonstrates understanding 
 How and why you should use a spacer  Demonstrates understanding 
 How to use a peak flow meter  Demonstrates understanding 
 Asthma triggers and how to handle them  Demonstrates understanding 
 Managing exercise induced asthma  Demonstrates understanding 
 Keeping track of symptoms    
 Using an asthma action plan    
Personal goals for asthma management: Wants to get rid of chest discomfort; Total minutes asthma education: 35 
Follow up plan: Schedule office visit with PCP ASAP, Follow up virtual visit in 2 weeks. Reinforced need to follow 
up in office ASAP; given # to call clinic since he did not have it. 
  
 
 
 
 
